Overcoming Therapeutic Resistance & Efficacy Challenges in RAS-Mutant Cancers with Certis Oncology Intelligence®
Time: 9:30 am
day: Day Two
Details:
• Exploring CertisAI™ to predict the response of- and identify predictive biomarkers for- RAS-targeted therapies, including novel drug combinations and monotherapies
• Mimicking clinical scenarios, including prior treatment, radiotherapy, acquired drug resistance, metastases and immune response to evaluate resistance mechanisms and design novel strategies for RAS-driven lung, colorectal and pancreatic cancers
• Tracking tumor burden, response, and pathophysiological processes in clinically relevant cancer models, using advanced multi-modality imaging
